[EN] LOW MOLECULAR WEIGHT PROTEIN DEGRADERS AND THEIR APPLICATIONS [FR] AGENTS DE DÉGRADATION DE PROTÉINES DE FAIBLE POIDS MOLÉCULAIRE ET LEURS APPLICATIONS
Discovery of CRBN E3 Ligase Modulator CC-92480 for the Treatment of Relapsed and Refractory Multiple Myeloma
摘要:
Many patients with multiple myeloma (MM) initially respond to treatment with modern combination regimens including immunomodulatory agents (lenalidomide and pomalidomide) and proteasome inhibitors. However, some patients lack an initial response to therapy (i.e., are refractory), and although the mean survival of MM patients has more than doubled in recent years, most patients will eventually relapse. To address this need, we explored the potential of novel cereblon E3 ligase modulators (CELMoDs) for the treatment of patients with relapsed or refractory multiple myeloma (RRMM). We found that optimization beyond potency of degradation, including degradation efficiency and kinetics, could provide efficacy in a lenalidomide-resistant setting. Guided by both phenotypic and protein degradation data, we describe a series of CELMoDs for the treatment of RRMM, culminating in the discovery of CC-92480, a novel protein degrader and the first CELMoD to enter clinical development that was specifically designed for efficient and rapid protein degradation kinetics.
Isoindole-imide compounds and compositions comprising and methods of using the same
申请人:Muller W. George
公开号:US20070049618A1
公开(公告)日:2007-03-01
This invention relates to isoindole-imide compounds, and pharmaceutically acceptable salts, solvates, stereoisomers, and prodrugs thereof. Methods of use, and pharmaceutical compositions of these compounds are disclosed.
Arylmethoxy Isoindoline Derivatives and Compositions Comprising and Methods of Using the Same
申请人:Man Hon-Wah
公开号:US20110196150A1
公开(公告)日:2011-08-11
Provided are 4′-arylmethoxy isoindoline compounds, and pharmaceutically acceptable salts, solvates, clathrates, stereoisomers, and prodrugs thereof. Methods of use, and pharmaceutical compositions of these compounds are disclosed.
ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME
申请人:Celgene Corporation
公开号:US20180037567A1
公开(公告)日:2018-02-08
Provided are 4′-arylmethoxy isoindoline compounds, and pharmaceutically acceptable salts, solvates, clathrates, stereoisomers, and prodrugs thereof. Methods of use, and pharmaceutical compositions of these compounds are disclosed.
5-Substituted quinazolinone derivatives and compositions comprising and methods of using the same
申请人:Muller George W.
公开号:US20080161328A1
公开(公告)日:2008-07-03
Provided are 5-substituted quinazolinone compounds, and pharmaceutically acceptable salts, solvates, clathrates, stereoisomers, and prodrugs thereof. Methods of use, and pharmaceutical compositions of these compounds are disclosed.